RxDoctor Payments Data

Wilfredo Cuevas

General Practice · San Lorenzo, PRNPI 1720296718

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $466,400 of the $529,618 with a category attached, or 88.1%. Viiv Healthcare Company accounts for 77.4% of it on its own, with 8 other manufacturers making up the rest. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$529,618in general payments, 2019–2025

Across 485 payments — averaging $1091.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$410K
  • Johnson & Johnson$85K
  • Janssen Scientific Affairs, LLC$10K
  • Merck$9K
  • Gilead$8K
  • Janssen Products, LP$7K
  • plus $800 from 3 others

What the payments were for

  • Consulting fees$38,3657%
  • Speaking & faculty fees$466,40088%
  • Travel & lodging$11,8762%
  • Food & beverage$12,6432%
  • Education$3340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529,618 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine387$1,244,130
TivicayDolutegravir Sodium180$487,531
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf86$439,656
JulucaDolutegravir/Rilpivirine100$389,648
BiktarvyBictegrav/Emtricit/Tenofov Ala87$380,909
DescovyEmtricitabine/Tenofov Alafenam118$270,481
PrezcobixDarunavir/Cobicistat54$134,388
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$103,017
CabenuvaCabotegravir/Rilpivirine12$78,108
Isentress HdRaltegravir Potassium29$58,282
PifeltroDoravirine24$41,661
EdurantRilpivirine Hcl23$34,759
SelzentryMaraviroc12$20,472
Maraviroc12$13,727
Etravirine13$7,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Cabenuva$410,068$2,199,418679 claims
GileadBiktarvy, Descovy$7,881$651,390205 claims
Janssen Products, LPSymtuza$6,979$439,65686 claims
Johnson & JohnsonPrezcobix$85,390$134,38854 claims
MerckIsentress Hd, Pifeltro$8,810$99,94253 claims
Janssen Scientific Affairs, LLCEdurant$9,690$34,75923 claims
AbbVieSynthroid$117$1,33716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in San Lorenzo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →